Integrity Alliance LLC. Invests $596,000 in Natera, Inc. $NTRA

Integrity Alliance LLC. bought a new position in Natera, Inc. (NASDAQ:NTRA) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor bought 2,603 shares of the medical research company’s stock, valued at approximately $596,000.

Several other institutional investors have also recently made changes to their positions in the company. JPMorgan Chase & Co. raised its position in shares of Natera by 9.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 11,628,914 shares of the medical research company’s stock worth $1,871,914,000 after acquiring an additional 1,003,129 shares in the last quarter. State Street Corp raised its position in shares of Natera by 2.2% in the 3rd quarter. State Street Corp now owns 3,389,599 shares of the medical research company’s stock worth $545,624,000 after acquiring an additional 72,087 shares in the last quarter. Franklin Resources Inc. grew its holdings in Natera by 37.5% in the third quarter. Franklin Resources Inc. now owns 2,665,013 shares of the medical research company’s stock worth $428,987,000 after purchasing an additional 727,366 shares during the period. Fred Alger Management LLC increased its stake in shares of Natera by 1.7% during the third quarter. Fred Alger Management LLC now owns 2,451,779 shares of the medical research company’s stock valued at $394,663,000 after purchasing an additional 41,303 shares in the last quarter. Finally, AQR Capital Management LLC increased its stake in shares of Natera by 39.0% during the third quarter. AQR Capital Management LLC now owns 2,400,065 shares of the medical research company’s stock valued at $386,338,000 after purchasing an additional 673,315 shares in the last quarter. Institutional investors own 99.90% of the company’s stock.

Insiders Place Their Bets

In related news, CEO Steven Leonard Chapman sold 5,838 shares of the company’s stock in a transaction that occurred on Monday, April 27th. The stock was sold at an average price of $204.14, for a total value of $1,191,769.32. Following the transaction, the chief executive officer directly owned 150,769 shares of the company’s stock, valued at approximately $30,777,983.66. This represents a 3.73% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Solomon Moshkevich sold 3,405 shares of the company’s stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $203.69, for a total value of $693,564.45. Following the completion of the transaction, the insider directly owned 142,295 shares in the company, valued at $28,984,068.55. This trade represents a 2.34% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders sold 41,356 shares of company stock valued at $8,374,584. Insiders own 5.63% of the company’s stock.

More Natera News

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Natera announced a new collaboration with Diakonos Oncology to use Signatera in a Phase I/II study for refractory melanoma, expanding a key cancer-testing product into another clinical use case and reinforcing its oncology growth story. Article Title
• Positive Sentiment: Canaccord raised its price target on Natera to $250 from $200, signaling stronger confidence in the company’s outlook and helping fuel bullish sentiment. Article Title
• Positive Sentiment: Natera is also drawing attention from investors after commentary calling it a favorite stock idea for the rest of 2026, which adds to the momentum around the name. Article Title

Natera Stock Up 4.4%

Natera stock opened at $223.37 on Friday. The company has a market capitalization of $31.99 billion, a P/E ratio of -137.04 and a beta of 1.57. The stock’s 50 day moving average is $202.37 and its 200 day moving average is $215.69. Natera, Inc. has a twelve month low of $131.81 and a twelve month high of $256.36.

Natera (NASDAQ:NTRA) last posted its quarterly earnings results on Thursday, February 26th. The medical research company reported $0.35 earnings per share for the quarter, topping the consensus estimate of ($0.46) by $0.81. The company had revenue of $665.50 million for the quarter, compared to the consensus estimate of $600.68 million. Natera had a negative return on equity of 14.74% and a negative net margin of 9.05%.During the same quarter in the prior year, the business posted ($0.41) EPS. As a group, equities analysts expect that Natera, Inc. will post -1.49 EPS for the current year.

Wall Street Analyst Weigh In

A number of analysts have recently commented on NTRA shares. Wells Fargo & Company boosted their price target on Natera from $215.00 to $220.00 and gave the stock an “equal weight” rating in a research report on Friday, May 8th. Morgan Stanley cut their price target on Natera from $265.00 to $250.00 and set an “overweight” rating on the stock in a research note on Tuesday, March 3rd. Piper Sandler restated an “overweight” rating and issued a $249.00 price target on shares of Natera in a research note on Tuesday, May 12th. Robert W. Baird set a $265.00 price target on Natera in a research note on Friday, May 8th. Finally, Wall Street Zen downgraded Natera from a “buy” rating to a “hold” rating in a research note on Saturday, May 9th. One analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $256.60.

Natera Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.